Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for XNCR

Stock NameXencor Inc
TickerXNCR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS98401F1057

Show aggregate XNCR holdings

News associated with XNCR

Barclays Initiates Coverage on Xencor (NASDAQ:XNCR)
Research analysts at Barclays began coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set an “underweight” rating and a $6.00 price target on the biopharmaceutical company’s stock. Barclays‘s price objective suggests a potential downside of 40.18% from the stock’s previous close. A number […] - 2025-09-19 02:46:44
Xencor (NASDAQ:XNCR) Shares Gap Down After Analyst Downgrade
Xencor, Inc. (NASDAQ:XNCR – Get Free Report)’s share price gapped down prior to trading on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The stock had previously closed at $8.55, but opened at $8.00. Bank of America now has a $12.00 price target on the stock, down […] - 2025-09-05 02:15:52
Xencor (NASDAQ:XNCR) vs. Enliven Therapeutics (NASDAQ:ELVN) Critical Comparison
Xencor (NASDAQ:XNCR – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk. Earnings & Valuation This table compares Xencor and […] - 2025-08-27 04:54:48
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target […] - 2025-08-22 02:42:55
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Alps Advisors Inc.
Alps Advisors Inc. lowered its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 9.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,459 shares of the biopharmaceutical company’s stock after selling 5,126 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:25:57
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by New York State Teachers Retirement System
New York State Teachers Retirement System boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,326 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during […] - 2025-07-11 05:14:58
Xencor (NASDAQ:XNCR) Trading Down 5.7% Following Insider Selling
Xencor, Inc. (NASDAQ:XNCR – Get Free Report) shares fell 5.7% during trading on Tuesday following insider selling activity. The stock traded as low as $8.67 and last traded at $8.53. 67,899 shares were traded during mid-day trading, a decline of 90% from the average session volume of 664,926 shares. The stock had previously closed at […] - 2025-06-19 02:13:09
Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Average Target Price from Analysts
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy […] - 2025-06-11 04:40:45
California State Teachers Retirement System Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)
California State Teachers Retirement System increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,130 shares of the biopharmaceutical company’s stock after buying an additional 6,376 shares during the period. […] - 2025-06-10 04:22:46
53,397 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Public Employees Retirement System of Ohio
Public Employees Retirement System of Ohio acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 53,397 shares of the biopharmaceutical company’s stock, valued at approximately $1,227,000. Other large investors have also modified their holdings of the company. Sterling Capital Management LLC boosted […] - 2025-06-03 05:30:52
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 23.4% in the 4th quarter, HoldingsChannel reports. The fund owned 40,355 shares of the biopharmaceutical company’s stock after purchasing an additional 7,650 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Xencor were […] - 2025-05-27 04:46:48
Head to Head Analysis: Xencor (NASDAQ:XNCR) versus Dermata Therapeutics (NASDAQ:DRMA)
Xencor (NASDAQ:XNCR – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations. Valuation and Earnings This table compares Xencor and […] - 2025-05-21 03:14:50
Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)
Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […] - 2025-05-13 02:04:46
Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Tower Research Capital LLC TRC
Tower Research Capital LLC TRC boosted its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 132.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,865 shares of the biopharmaceutical company’s stock after purchasing an additional 4,482 shares during the quarter. Tower Research […] - 2025-05-06 05:17:02
Dimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)
Dimensional Fund Advisors LP grew its position in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,501,532 shares of the biopharmaceutical company’s stock after purchasing an additional 102,297 shares during the period. Dimensional Fund […] - 2025-05-05 05:21:10
10,408 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Bank of Montreal Can
Bank of Montreal Can purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $239,000. Several other institutional investors have also added to or reduced their stakes in XNCR. Finepoint Capital LP […] - 2025-04-25 04:36:48
William Blair Begins Coverage on Xencor (NASDAQ:XNCR)
Research analysts at William Blair initiated coverage on shares of Xencor (NASDAQ:XNCR – Get Free Report) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on the company. Wells Fargo & Company dropped their […] - 2025-04-23 02:11:01
Xencor, Inc. (NASDAQ:XNCR) Stake Lifted by Legal & General Group Plc
Legal & General Group Plc lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 191,514 shares of the biopharmaceutical company’s stock after acquiring an additional 20,141 shares during the quarter. […] - 2025-04-22 04:47:07
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Russell Investments Group Ltd.
Russell Investments Group Ltd. lessened its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 216,291 shares of the biopharmaceutical company’s stock after selling 16,734 shares during the quarter. Russell Investments […] - 2025-04-15 05:33:08
Pictet Asset Management Holding SA Invests $247,000 in Xencor, Inc. (NASDAQ:XNCR)
Pictet Asset Management Holding SA acquired a new stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 10,740 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Several other hedge funds and other institutional investors also recently added to or reduced their stakes […] - 2025-04-11 05:58:59
Norges Bank Makes New Investment in Xencor, Inc. (NASDAQ:XNCR)
Norges Bank acquired a new stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 147,823 shares of the biopharmaceutical company’s stock, valued at approximately $3,397,000. A number of other institutional investors and hedge funds have also recently […] - 2025-04-11 05:12:49
Xencor, Inc. (NASDAQ:XNCR) Stock Position Lifted by Vanguard Group Inc.
Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,017,366 shares of the biopharmaceutical company’s stock after acquiring an additional 418,040 shares during the period. Vanguard Group Inc. owned 0.11% of Xencor worth $184,239,000 as of its […] - 2025-04-07 05:06:58
Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Prudential Financial Inc.
Prudential Financial Inc. increased its position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,715 shares of the biopharmaceutical company’s stock after acquiring an additional 6,810 shares during […] - 2025-04-06 05:30:53
Teacher Retirement System of Texas Buys 3,250 Shares of Xencor, Inc. (NASDAQ:XNCR)
Teacher Retirement System of Texas boosted its stake in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 21.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,645 shares of the biopharmaceutical company’s stock after purchasing an additional 3,250 shares during […] - 2025-04-01 04:40:45
Thrivent Financial for Lutherans Has $2.82 Million Stock Position in Xencor, Inc. (NASDAQ:XNCR)
Thrivent Financial for Lutherans grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,897 shares of the biopharmaceutical company’s stock after buying an additional 6,528 shares during the quarter. Thrivent Financial […] - 2025-03-28 06:18:47
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Buy” from Analysts
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average […] - 2025-03-25 04:26:50
Analysts Forecast 25% Upside For VB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-21 08:40:03
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by US Bancorp DE
US Bancorp DE cut its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 75.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,532 shares of the biopharmaceutical company’s stock after selling 7,843 shares during the period. US Bancorp DE’s holdings in Xencor were […] - 2025-03-19 05:10:48
Wells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00
Xencor (NASDAQ:XNCR – Free Report) had its target price lowered by Wells Fargo & Company from $37.00 to $33.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. […] - 2025-03-03 04:21:01
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Xencor, Inc. (NASDAQ:XNCR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-02-28 06:35:19

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) XNCR holdings

DateNumber of XNCR Shares HeldBase Market Value of XNCR SharesLocal Market Value of XNCR SharesChange in XNCR Shares HeldChange in XNCR Base ValueCurrent Price per XNCR Share HeldPrevious Price per XNCR Share Held
2025-11-11 (Tuesday)45,811USD 681,210XNCR holding increased by 51767USD 681,2100USD 51,767 USD 14.87 USD 13.74
2025-11-10 (Monday)45,811XNCR holding increased by 118USD 629,443XNCR holding decreased by -5690USD 629,443118USD -5,690 USD 13.74 USD 13.9
2025-11-07 (Friday)45,693USD 635,133XNCR holding decreased by -4569USD 635,1330USD -4,569 USD 13.9 USD 14
2025-11-06 (Thursday)45,693XNCR holding increased by 118USD 639,702XNCR holding decreased by -15211USD 639,702118USD -15,211 USD 14 USD 14.37
2025-11-05 (Wednesday)45,575USD 654,913XNCR holding increased by 30535USD 654,9130USD 30,535 USD 14.37 USD 13.7
2025-11-04 (Tuesday)45,575XNCR holding increased by 118USD 624,378XNCR holding decreased by -9293USD 624,378118USD -9,293 USD 13.7 USD 13.94
2025-11-03 (Monday)45,457USD 633,671XNCR holding decreased by -35001USD 633,6710USD -35,001 USD 13.94 USD 14.71
2025-10-31 (Friday)45,457USD 668,672XNCR holding increased by 26365USD 668,6720USD 26,365 USD 14.71 USD 14.13
2025-10-30 (Thursday)45,457XNCR holding increased by 590USD 642,307XNCR holding decreased by -15892USD 642,307590USD -15,892 USD 14.13 USD 14.67
2025-10-29 (Wednesday)44,867XNCR holding increased by 238USD 658,199XNCR holding increased by 22236USD 658,199238USD 22,236 USD 14.67 USD 14.25
2025-10-28 (Tuesday)44,629USD 635,963XNCR holding decreased by -893USD 635,9630USD -893 USD 14.25 USD 14.27
2025-10-27 (Monday)44,629USD 636,856XNCR holding increased by 47307USD 636,8560USD 47,307 USD 14.27 USD 13.21
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of XNCR by Blackrock for IE00BYXG2H39

Show aggregate share trades of XNCR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY118 13.740* 13.57
2025-11-06BUY118 14.000* 13.56
2025-11-04BUY118 13.700* 13.56
2025-10-30BUY59014.88014.060 14.142USD 8,344 13.55
2025-10-29BUY23814.67015.500 15.417USD 3,669 13.54
2025-10-22SELL-47213.29014.590 14.460USD -6,825 13.54 Loss of -432 on sale
2025-10-20BUY23615.07015.685 15.624USD 3,687 13.53
2025-10-17BUY58914.77015.070 15.040USD 8,859 13.52
2025-10-15BUY93614.10014.250 14.235USD 13,324 13.52
2025-10-03BUY83311.77012.115 12.080USD 10,063 13.54
2025-10-02BUY11911.82012.020 12.000USD 1,428 13.55
2025-09-30BUY23811.73011.875 11.860USD 2,823 13.57
2025-09-26BUY23811.57011.715 11.701USD 2,785 13.59
2025-09-25BUY23810.33010.480 10.465USD 2,491 13.61
2025-09-24SELL-3,48110.47010.660 10.641USD -37,041 13.63 Profit of 10,395 on sale
2025-09-18BUY13110.03010.170 10.156USD 1,330 13.65
2025-09-17BUY3939.2509.505 9.480USD 3,725 13.67
2025-08-20SELL-5207.5107.734 7.712USD -4,010 13.81 Profit of 3,173 on sale
2025-07-30BUY5128.7309.210 9.162USD 4,691 14.03
2025-07-17SELL-2589.0709.190 9.178USD -2,368 14.32 Profit of 1,328 on sale
2025-07-11SELL-1,0328.8309.195 9.158USD -9,452 14.48 Profit of 5,487 on sale
2025-07-07BUY3877.9408.440 8.390USD 3,247 14.64
2025-07-02BUY7,1508.3008.570 8.543USD 61,082 14.73
2025-06-20BUY3,1858.5408.730 8.711USD 27,745 14.77
2025-06-11BUY2389.5209.980 9.934USD 2,364 15.08
2025-06-10BUY2389.74010.200 10.154USD 2,417 15.12
2025-06-04SELL-1199.1009.600 9.550USD -1,136 15.30 Profit of 684 on sale
2025-04-23BUY11810.87012.430 12.274USD 1,448 17.26
2025-04-10SELL-9447.9208.620 8.550USD -8,071 18.04 Profit of 8,963 on sale
2025-04-08SELL-1187.6708.580 8.489USD -1,002 18.27 Profit of 1,154 on sale
2025-04-07SELL-1188.3708.975 8.915USD -1,052 18.39 Profit of 1,118 on sale
2025-04-04SELL-5958.6908.870 8.852USD -5,267 18.50 Profit of 5,740 on sale
2025-04-01BUY4849.69010.590 10.500USD 5,082 18.71
2025-03-31SELL-35710.64011.215 11.158USD -3,983 18.81 Profit of 2,731 on sale
2025-03-21BUY1,89113.20013.470 13.443USD 25,421 19.35
2025-03-14SELL-1,80812.76013.120 13.084USD -23,656 19.80 Profit of 12,136 on sale
2025-03-07SELL-22413.87014.020 14.005USD -3,137 20.28 Profit of 1,406 on sale
2025-03-04SELL-11214.15014.415 14.388USD -1,612 20.58 Profit of 694 on sale
2025-02-25BUY22414.45015.230 15.152USD 3,394 21.09
2025-02-19SELL-11216.20016.685 16.636USD -1,863 21.49 Profit of 543 on sale
2025-02-13BUY33316.29016.700 16.659USD 5,547 21.90
2025-02-12BUY11116.22016.250 16.247USD 1,803 22.02
2025-02-11BUY44416.13016.645 16.594USD 7,368 22.14
2025-01-02BUY1,00923.79024.000 23.979USD 24,195 23.55
2024-12-30SELL-54123.71024.075 24.039USD -13,005 23.55 Loss of -266 on sale
2024-11-18SELL-1,60523.19023.440 23.415USD -37,581 21.77 Loss of -2,634 on sale
2024-11-08SELL-10723.62023.880 23.854USD -2,552 21.50 Loss of -251 on sale
2024-10-21SELL-10821.08021.590 21.539USD -2,326 0.00 Loss of -2,326 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of XNCR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19441,0430699,16963.1%
2025-09-18355,3200679,37252.3%
2025-09-17293,2590484,81960.5%
2025-09-16102,8170219,24846.9%
2025-09-15305,8570441,74769.2%
2025-09-12139,1840241,19757.7%
2025-09-11116,0850466,59524.9%
2025-09-10131,9410251,55052.5%
2025-09-0965,6930308,39121.3%
2025-09-08129,6770214,36560.5%
2025-09-05110,5730181,05261.1%
2025-09-0469,3150426,04716.3%
2025-09-03131,0610222,78058.8%
2025-09-02113,8830274,94441.4%
2025-08-29109,9640426,34125.8%
2025-08-2890,0020140,21764.2%
2025-08-27296,4420650,72345.6%
2025-08-26144,4500345,86941.8%
2025-08-25119,73693238,93750.1%
2025-08-22195,2100362,90653.8%
2025-08-2151,99810096,81053.7%
2025-08-2035,4685162,33356.9%
2025-08-1969,0730115,30259.9%
2025-08-1878,7160116,55267.5%
2025-08-1556,5530121,85746.4%
2025-08-1483,8250189,10244.3%
2025-08-1394,7380327,89928.9%
2025-08-12139,6400379,02436.8%
2025-08-11145,5580325,98644.7%
2025-08-08139,4270278,21050.1%
2025-08-07167,69625428,18839.2%
2025-08-06117,30061197,83359.3%
2025-08-0586,4000230,65737.5%
2025-08-0479,1790198,92739.8%
2025-08-01100,4530414,16624.3%
2025-07-3194,62383234,87040.3%
2025-07-30168,9100227,32074.3%
2025-07-2971,6720104,99168.3%
2025-07-2889,9570120,69074.5%
2025-07-2578,0770136,93257.0%
2025-07-24116,7600178,38465.5%
2025-07-23179,8650277,40564.8%
2025-07-22106,6133,584223,16447.8%
2025-07-2172,4760170,10842.6%
2025-07-1872,2270112,64364.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.